Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 10/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16400521 | 0.87 | KMT2A (0.67) | KMT2AHPGDPTPN2PTPN1PTPN6 | |
| SCHEMBL8284375 | 0.84 | KMT2A (0.55) | KMT2AHPGDPTPN2PTPN1PTPN6 | |
| SCHEMBL8284357 | 0.83 | KMT2A (0.57) | KMT2AHPGDPTPN2PTPN1PTPN6 | |
| SCHEMBL12513264 | 0.82 | KMT2A (0.62) | KMT2AHPGDPTPN2PTPN1PTPN6 | |
| SCHEMBL3296996 | 0.81 | HPGD (0.59) | KMT2AHPGDPTPN2PTPN1PTPN6 | |
| SCHEMBL4206232 | 0.80 | EPHX1 (0.63) | KMT2AHPGDPTPN2PTPN1PTPN6 | |
| SCHEMBL10189967 | 0.80 | KMT2A (0.54) | KMT2AHPGDPTPN2PTPN1PTPN6 | |
| SCHEMBL12069934 | 0.79 | KMT2A (0.58) | KMT2AHPGDPTPN2PTPN1PTPN6 | |
| SCHEMBL8549425 | 0.79 | KMT2A (0.58) | KMT2AHPGDPTPN2PTPN1PTPN6 | |
| SCHEMBL31706334 | 0.78 | KMT2A (0.58) | KMT2AHPGDPTPN2PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| US-7442795-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1558598-A1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | Pfizer Limited (GB) | 2005-08-03 | — | — | EP | disclosed |
| WO-2005068466-A1 | COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005063754-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005063754-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-07-14 | — | — | WO | disclosed |
| US-20050154024-A1 | Compounds useful in therapy | PFIZER INC | 2005-07-14 | — | — | US | disclosed |
| US-20040186091-A1 | A bi-heterocycle-4H-2,3,5,10b-tetraaza-benzo[e]azulene derivatives; for therapy of dysmenorrhoea, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease, cataract, central nervous system disease, motion sickness, Raynaud's disease, rheumatoid arthritis; chemical synthesis | PFIZER INC | 2004-09-23 | — | — | US | disclosed |
| WO-2004074291-A1 | TRIAZOLE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074291-A1 | TRIAZOLE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2004-09-02 | — | — | WO | disclosed |
| US-20040162278-A1 | Triazole compounds useful in therapy | PFIZER INC | 2004-08-19 | — | — | US | disclosed |
| WO-2004037809-A1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162278-A1 | Triazole compounds useful in therapy | AVPR2, AVPR1B, AVPR1A | KMT2A 4439/4885HPGD 1209/4885PTPN2 4608/4885 |
| US-20050154024-A1 | Compounds useful in therapy | PTGER4, PTGER3, ALOX5 | KMT2A 3968/4885HPGD 350/4885PTPN2 3914/4885 |
| US-20040186091-A1 | A bi-heterocycle-4H-2,3,5,10b-tetraaza-benzo[e]azulene derivatives; for therapy of dysmenorrhoea, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease, cataract, central nervous system disease, motion sickness, Raynaud's disease, rheumatoid arthritis; chemical synthesis | CNR1, NR1H2, OXER1 | KMT2A 4063/4885HPGD 621/4885PTPN2 4364/4885 |
| US-20100317652-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | KMT2A 1134/4885HPGD 486/4885PTPN2 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.